Yoko Yamana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yoko Yamana has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Aya Hojo
Division of Gastroenterology and Hepatology, Toho University Omori Medical Center, Tokyo, Japan
2 shared publications - Masa Maeda
Center for Advanced IBD Research and Treatment Kitasato University Kitasato Institute Hospital Tokyo Japan
2 shared publications - Masaru Nakano
Center for Advanced IBD Research and Treatment Kitasato University Kitasato Institute Hospital Tokyo Japan
2 shared publications - Ryo Karashima
Center for Advanced IBD Research and Treatment Kitasato University Kitasato Institute Hospital Minato‐ku Tokyo Japan
2 shared publications - Shintaro Sagami
Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan
2 shared publications - Takahisa Matsuda
Toho University Omori Medical Center, Japan
2 shared publications
Latest Publications
- 6 December 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (4) , 658-666
Leucine‐Rich Alpha‐2 Glycoprotein Is Associated With Transmural Inflammation Assessed by Intestinal Ultrasound in Patients With Crohn's Disease
Background: Intestinal ultrasound (IUS) is a non‐invasive tool for evaluating transmural inflammation in Crohn's disease (CD). However, its utility is constrained by operator dependency and limited accessibility.Aims: To explore the feasibility of serum biomarkers—specifically leucine‐rich alpha‐2 glycoprotein (LRG)—as an alternative to IUS for assessing transmural inflammation.Methods: This retrospective, single‐centre study included patients with CD who underwent IUS and measurements of LRG and C‐reactive protein (CRP). We assessed correlations between biomarkers and five IUS scores (Limberg score, Bowel Ultrasound Score (BUSS), International Bowel Ultrasound Segmental Activity Score (IBUS‐SAS), Simple Ultrasound Score (Simple‐US) and Simple Ultrasound Score for Crohn's Disease (SUS‐CD)) using receiver operator characteristic curve analysis and Spearman's rank correlation coefficient. We conducted subgroup analyses for patients in clinical remission.Results: We analysed 213 IUS examinations performed on 97 patients; 170 (80%) IUS were during clinical remission. The area under the curve for LRG for each IUS score (0.76, 0.80, 0.77, 0.75 and 0.69, respectively) was superior to that of CRP and was statistically significant, particularly for LS, BUSS, IBUS‐SAS and Simple‐US (p < 0.001, p = 0.018, p < 0.001 and p < 0.001, respectively). Predictive values remained consistent among patients in remission. LRG demonstrated excellent correlation with IUS scores in both the overall patient population and those in remission.Conclusion: LRG showed a robust correlation with IUS scores, suggesting its potential as a novel indicator for targeting transmural healing in patients with CD.
- 6 December 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 61 (4) , 658-666
Leucine‐Rich Alpha‐2 Glycoprotein Is Associated With Transmural Inflammation Assessed by Intestinal Ultrasound in Patients With Crohn's Disease
Background: Intestinal ultrasound (IUS) is a non‐invasive tool for evaluating transmural inflammation in Crohn's disease (CD). However, its utility is constrained by operator dependency and limited accessibility.Aims: To explore the feasibility of serum biomarkers—specifically leucine‐rich alpha‐2 glycoprotein (LRG)—as an alternative to IUS for assessing transmural inflammation.Methods: This retrospective, single‐centre study included patients with CD who underwent IUS and measurements of LRG and C‐reactive protein (CRP). We assessed correlations between biomarkers and five IUS scores (Limberg score, Bowel Ultrasound Score (BUSS), International Bowel Ultrasound Segmental Activity Score (IBUS‐SAS), Simple Ultrasound Score (Simple‐US) and Simple Ultrasound Score for Crohn's Disease (SUS‐CD)) using receiver operator characteristic curve analysis and Spearman's rank correlation coefficient. We conducted subgroup analyses for patients in clinical remission.Results: We analysed 213 IUS examinations performed on 97 patients; 170 (80%) IUS were during clinical remission. The area under the curve for LRG for each IUS score (0.76, 0.80, 0.77, 0.75 and 0.69, respectively) was superior to that of CRP and was statistically significant, particularly for LS, BUSS, IBUS‐SAS and Simple‐US (p < 0.001, p = 0.018, p < 0.001 and p < 0.001, respectively). Predictive values remained consistent among patients in remission. LRG demonstrated excellent correlation with IUS scores in both the overall patient population and those in remission.Conclusion: LRG showed a robust correlation with IUS scores, suggesting its potential as a novel indicator for targeting transmural healing in patients with CD.
- Open Access
- 30 October 2024
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 22 (4) , 473-483
Early change in serum leucine-rich α-2-glycoprotein predicts clinical and endoscopic response in ulcerative colitis
Background/Aims: Leucine-rich α-2-glycoprotein (LRG) is a new serum biomarker reflecting the disease activity of ulcerative colitis (UC), but its change during the acute phase has not been enough investigated. Methods: Patients with UC who initiated the induction therapy with steroid or advanced therapy (biologics or Janus kinase inhibitors) were prospectively enrolled. Associations of LRG, C-reactive protein (CRP) and fecal calprotectin (FC) at baseline, week 1, and week 8 with clinical remission at week 8 and subsequent endoscopic improvement within 1 year (Mayo endoscopic subscore of 0 or 1) were assessed. Results: A total of 143 patients with UC were included. LRG and CRP at week 1 were significantly lower in the clinical remission group than in the non-remission group (LRG, 20.6 μg/mL vs. 28.4 μg/mL, P< 0.001; CRP, 0.9 mg/dL vs. 2.3 mg/dL, P< 0.001) while FC demonstrated the difference between groups only at week 8. The area under the curves of week 1 LRG, CRP, and FC for week 8 clinical remission using the receiver operating characteristic curves analysis were 0.68, 0.71, and 0.57, respectively. Furthermore, LRG and CRP predicted subsequent endoscopic improvement as early as week 1, while FC was predictive only at week 8. Conclusions: LRG can be an early-phase biomarker predicting subsequent clinical and endoscopic response to induction therapy.
- 30 October 2024
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 22 (4) , 473-483
Open AccessEarly change in serum leucine-rich α-2-glycoprotein predicts clinical and endoscopic response in ulcerative colitis
Background/Aims: Leucine-rich α-2-glycoprotein (LRG) is a new serum biomarker reflecting the disease activity of ulcerative colitis (UC), but its change during the acute phase has not been enough investigated. Methods: Patients with UC who initiated the induction therapy with steroid or advanced therapy (biologics or Janus kinase inhibitors) were prospectively enrolled. Associations of LRG, C-reactive protein (CRP) and fecal calprotectin (FC) at baseline, week 1, and week 8 with clinical remission at week 8 and subsequent endoscopic improvement within 1 year (Mayo endoscopic subscore of 0 or 1) were assessed. Results: A total of 143 patients with UC were included. LRG and CRP at week 1 were significantly lower in the clinical remission group than in the non-remission group (LRG, 20.6 μg/mL vs. 28.4 μg/mL, P< 0.001; CRP, 0.9 mg/dL vs. 2.3 mg/dL, P< 0.001) while FC demonstrated the difference between groups only at week 8. The area under the curves of week 1 LRG, CRP, and FC for week 8 clinical remission using the receiver operating characteristic curves analysis were 0.68, 0.71, and 0.57, respectively. Furthermore, LRG and CRP predicted subsequent endoscopic improvement as early as week 1, while FC was predictive only at week 8. Conclusions: LRG can be an early-phase biomarker predicting subsequent clinical and endoscopic response to induction therapy.